Zomedica Acquires the Assets of Leading tPEM(TM) Company Assisi Animal Health – Form 8-K

0

Zomedica acquires the assets of leading tPEM(TM) company Assisi Animal Health

ANN ARBOR, MI /ACCESSWIRE/July 18, 2022/ Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company providing diagnostic and therapeutic products for companion animals, today announced that it has acquired substantially all of the assets of ‘Assisi Animal Health LLC (“Assisi”).

Assisi has created an innovative line of Targeted Pulsed Electromagnetic Field (tPEMF™) devices for pets that provide a safe, drug-free alternative for the treatment of pain, inflammation, anxiety or mood disorders. behaviour. PEMF technology was cleared for use in humans in 2010, and since 2013 Assisi has conducted clinical studies using tPEMF technology and its effectiveness in managing pain, advancing healing, and controlling anxiety in pets. Assisi products are backed by major, benchmark and peer-reviewed clinical studies and publications (Research and clinical studies | Animal Health Meeting) and are backed by more than 40 key veterinary opinion leaders around the world. Assisi Loop® products are world leaders in front-line and alternative tPEMF therapy and are sold worldwide to help reduce pain and inflammation in the animals we share our lives with. They are available from veterinarians and several additional sales channels.

“Assisi Animal Health and the Loop product line has been a passionate commitment for the Assisi team since day one,” said Francis Russo, Managing Director of Assisi Animal Health. “We knew this technology could help animals live fuller, pain-free lives and we focused on making it available to everyone who needed it. We partnered with the veterinary community to refine and develop our products, to sponsor rigorous clinical research, and to create a market for our proprietary tPEMF therapy. Assisi products have already helped over 100,000 pets over the past eight years. With this acquisition, we are excited to see where Zomedica will take the next loop and how many more pets will be helped.”

“The integration of tPEMP technology alongside focused shockwave energy will not only enable comfortable treatment for many animal species, but will also advance integration modalities for a variety of conditions,” said said Adam Christman, DVM, MBA. “This incredibly progressive technology will continue to advance and elevate veterinary care.”

“This acquisition adds a growing product line that reinforces our commitment to providing solutions that deliver enhanced pet care, while improving practice efficiency and economy,” said Larry Heaton, President and CEO. General of Zomedica. “Assissi products fit perfectly into our growing therapeutic segment. They are complementary to PulseVet® shockwave therapy, in that they are designed to be used after shockwave therapy has been administered in the clinic, by the pet’s parent at home, and are provided by veterinarians to pet owners to prolong therapy.We are pleased to offer an additional drug-free solution to enhance the ability of our pets to live without pain.

Greg Blair, vice president of business development and strategic planning for Zomedica, led the company’s acquisition initiative. Maslon LLP acted as legal counsel to Zomedica in this transaction.

About Assisi Animal Health

A leader in targeted pulsed electromagnetic field (tPEMF) veterinary technology, Animal Health Meeting offers drug-free devices that reduce inflammation and are specifically designed to decrease pain and speed healing, as well as reduce canine separation anxiety. Assisi is committed to improving the quality of life for pets, their owners and veterinary professionals by creating safe and effective products backed by rigorous research for all animals in need of relief from pain, inflammation and anxiety. To find out more log on to assisianimalhealth.com.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company that creates companion animal products with a focus on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that focus on patient health and practice health. Zomedica’s mission is to provide veterinarians with the ability to increase their productivity and revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

Notice to readers

Except for statements of historical fact, this press release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is often characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other words similar, or statements that certain events or conditions “may” or “will” and include statements regarding our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Accordingly, there can be no assurance that actual results achieved will be the same, in whole or in part, as those set forth in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management as of the date the statements are made, including assumptions regarding the ability to transfer assets from Assisi to Zomedica facilities, economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, our ability to successfully integrate and operate the Assisi business, the adequacy of our budgeted capital and operating expenditures, the cost, the adequacy and availability of supplies needed for our operations, the fulfillment by our strategic partners of their obligations under our trade agreements, our ability to execute our business plans and our cost control efforts and the impact of COVID-19 on our activities, our results and our financial situation.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause actual results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will produce the benefits discounted; uncertainty regarding the timing and results of development work and verification and validation studies; uncertainty about the timing and results of marketing efforts, as well as the cost of marketing efforts, including the cost of developing an internal sales force and managing our growth; uncertainty about our ability to successfully integrate and operate the Assisi business; uncertainty about our ability to supply equipment and analytics in response to customer demand; uncertainty regarding the cost, adequacy and availability of supplies needed for our operations; uncertainty about the likelihood and timing of required regulatory approvals, as well as the availability and cost of capital; the ability to identify, develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditure necessary to maintain and improve the quality of products and services; technological developments and changes in laws and regulations; our ability to secure and maintain strategic relationships; the performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations: risks related to permits and licenses, risks of intellectual property infringement, risks related to possible clinical trials and approvals regulatory requirements, risks related to the safety and efficacy of our products, the use of our products, the protection of intellectual property, risks related to the COVID-19 pandemic and its impact on our business operations in general , including our ability to develop and commercialize our products, and other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be considered exhaustive.

The forward-looking information contained in this press release is expressly qualified by this cautionary statement. We undertake no obligation to update forward-looking information to conform to actual results or to changes in our expectations, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking information.

Contact with Investor Relations:

PCG Advisory Group

Kirin Smith, President

[email protected]

+1.646.823.8656

THE SOURCE: Zomedica Corp.

Share.

Comments are closed.